About Enobia Pharma
Enobia Pharma is a company based in Quebec City (Canada) founded in 1997 was acquired by Alexion in December 2011. Enobia Pharma has raised $138.52 million across 5 funding rounds from investors including Alexion, Desjardins and Orbimed. Enobia Pharma operates in a competitive market with competitors including NGM Biopharmaceuticals, MannKind Corp, Rhythm Pharmaceuticals, Horizon Therapeutics and Corcept, among others.
- Headquarter Quebec City, Canada
-
Sectors
Healthcare
-
Phone
Locked
-
Website
Locked
-
Social
Locked
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Funding Insights of Enobia Pharma
Enobia Pharma has successfully raised a total of $138.52M across 5 strategic funding rounds. The most recent funding activity was a Series D round of $20 million completed in August 2011. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in Enobia Pharma
Enobia Pharma has secured backing from 8 investors, including venture fund and institutional investors. Prominent investors backing the company include Alexion, Desjardins and Orbimed.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Investments are made by OrbiMed in global healthcare innovations across biopharmaceuticals and related fields.
|
Locked | Locked | Locked | |
|
CTI Capital is engaged in securities brokerage and venture capital investment.
|
Locked | Locked | Locked | |
|
-
|
Locked | Locked | Locked |
Investor details for Enobia Pharma
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Enobia Pharma
Investment portfolio details for Enobia Pharma
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - Enobia Pharma
Detailed financials for Enobia Pharma
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Enobia Pharma Comparisons
Peer comparison for Enobia Pharma
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Enobia Pharma
Enobia Pharma operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as NGM Biopharmaceuticals, MannKind Corp, Rhythm Pharmaceuticals, Horizon Therapeutics and Corcept, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Biologics are developed for cardio-metabolic and liver diseases.
|
|
| Locked | Locked | Locked |
Developer of small-molecule drugs
|
|
| Locked | Locked | Locked |
Developer of peptide therapeutics for the treatment of rare genetic deficiencies
|
|
| Locked | Locked | Locked |
Developer of drugs for treating rare and autoimmune diseases
|
|
| Locked | Locked | Locked |
Developer of cortisol modulators for the treatment of various diseases
|
|
| Locked | Locked | Locked |
Cell therapy for diabetes is developed from stem cells.
|
Detailed competitors of Enobia Pharma
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Enobia Pharma
Complete news archive for Enobia Pharma
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Enobia Pharma
Enobia Pharma was founded in 1997 and raised its 1st funding round 8 years after it was founded.
Enobia Pharma is headquartered in Quebec City, Canada. It is registered at Quebec City, Quebec, Canada.
Enobia Pharma is a funded company, having raised a total of $138.52M across 5 funding rounds to date.
Enobia Pharma was founded in 1997 in Quebec City, Canada, within the biotechnology sector. Focus is placed on creating treatments for severe genetic metabolic bone disorders lacking approved options. Operations involve research and development of therapeutic candidates. The primary product, ENB-0040, targets hypophosphatasia, which leads to skeletal deformities, muscle weakness, and damage to vital organs. Activities are centered in Canada.
Enobia Pharma's top competitors include Rhythm Pharmaceuticals, MannKind Corp and Corcept.
Enobia Pharma has 8 investors. Key investors include Alexion, Desjardins, Orbimed, CTI Capital, and Lothian Partners.